Shots:

• The CHMP’s positive recommendation is based on P-III IMpower133 study results assessing Tecentriq + CT vs CT (carboplatin and etoposide) in 403 patients in a ratio (1:1) with ES-SCLC
• The P-III IMpower133 study results: OS (12.3 vs 10.3 mos.); PFS (5.2 vs 4.3 mos.). Tecentriq based combination therapy is expecting its European Commission’s approval following the CHMP’s positive recommendation
• Tecentriq is a mAb targeting PD-L1- blocking its interaction with PD-1 and B7.1 receptor- thus enabling the interaction of T-cells and is an approved therapy for multiple cancer indications in the US & EU

Click here to­ read full press release/ article

Ref: Roche | Image: Roche